A detailed history of Corton Capital Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Corton Capital Inc. holds 9,839 shares of EXEL stock, worth $344,856. This represents 0.13% of its overall portfolio holdings.

Number of Shares
9,839
Holding current value
$344,856
% of portfolio
0.13%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.96 - $27.6 $216,064 - $271,556
9,839 New
9,839 $255,000
Q1 2022

May 16, 2022

SELL
$17.03 - $22.67 $351,005 - $467,251
-20,611 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$15.84 - $21.88 $326,478 - $450,968
20,611 New
20,611 $377,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.3B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Corton Capital Inc. Portfolio

Follow Corton Capital Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Corton Capital Inc., based on Form 13F filings with the SEC.

News

Stay updated on Corton Capital Inc. with notifications on news.